Express Scripts says AbbVie drug could displace Sovaldi on formulary
October 29, 2014 at 13:59 PM EDT
Oct 29 (Reuters) - Pharmacy benefit manager Express Scripts Holding Co said it may quickly change its preferred drug formulary to favor an expected new hepatitis C drug from AbbVie if it is clinically equivalent and less costly than Gilead Science Inc's $84,000 Sovaldi and $94,500 Harvoni treatments.